Patents by Inventor Jamie Campbell

Jamie Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES, USES & METHODS
    Publication number: 20240132605
    Abstract: The present invention related to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: August 3, 2023
    Publication date: April 25, 2024
    Inventors: Jamie CAMPBELL, Steve HOLMES, Ian KIRBY, Miha KOSMAC
  • Anti-PD-L1 and IL-2 cytokines
    Patent number: 11965026
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: April 23, 2024
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Cecilia Deantonio, Stephen Douglas Gillies
  • MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
    Publication number: 20230312720
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: September 1, 2022
    Publication date: October 5, 2023
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Ian KIRBY, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • Antibodies, uses and methods
    Patent number: 11773175
    Abstract: The present invention related to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: October 3, 2023
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • Nucleic acids encoding anti-OX40L antibodies
    Patent number: 11753479
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: September 12, 2023
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
    Publication number: 20230192859
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: June 20, 2017
    Publication date: June 22, 2023
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
    Publication number: 20220372153
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: April 20, 2022
    Publication date: November 24, 2022
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • Methods of treating comprising administering anti-OX40L antibodies
    Patent number: 11396550
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: July 26, 2022
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • BINDING MOLECULES BINDING PD-L1 AND LAG-3
    Publication number: 20220185894
    Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 16, 2022
    Applicant: F-star Therapeutics Limited
    Inventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis
  • Binding molecules binding PD-L1 and LAG-3
    Patent number: 11214620
    Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 4, 2022
    Assignee: F-star Therapeutics Limited
    Inventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis
  • ANTIBODIES, USES & METHODS
    Publication number: 20210395378
    Abstract: The present invention related to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: July 30, 2021
    Publication date: December 23, 2021
    Inventors: Jamie CAMPBELL, Steve HOLMES, Ian KIRBY, Miha KOSMAC
  • ANTI-PD-L1 ANTIBODIES
    Publication number: 20210380699
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: April 28, 2021
    Publication date: December 9, 2021
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • ANTIBODIES, USES & METHODS
    Publication number: 20210087287
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 25, 2021
    Applicant: Kymab Limited
    Inventors: Jamie CAMPBELL, Steve HOLMES, Ian KIRBY, Miha KOSMAC
  • Anti-OX40L antibodies and methods of treating graft versus host disease
    Patent number: 10669342
    Abstract: The present invention relates to anti-human OX4OL antibodies, new medical uses and methods.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: June 2, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosma{hacek over (c)}
  • Methods of treating SLE with anti-OX40L antibodies
    Patent number: 10654935
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: May 19, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosma{hacek over (c)}
  • Antibodies and immunocytokines
    Patent number: 10604576
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: March 31, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy Nee Waddell, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • ANTI-PD-L1 AND IL-2 CYTOKINES
    Publication number: 20190338032
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: June 20, 2017
    Publication date: November 7, 2019
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, IAN KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stphen Douglas GILLIES
  • ANTI-PD-L1 ANTIBODIES
    Publication number: 20190330351
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 31, 2019
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • ANTIBODIES, USES & METHODS
    Publication number: 20190276547
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: November 13, 2018
    Publication date: September 12, 2019
    Applicant: Kymab Limited
    Inventors: Jamie CAMPBELL, Steve HOLMES, Ian KIRBY, Miha KOSMAC
  • BINDING MOLECULES BINDING PD-L1 AND LAG-3
    Publication number: 20190256602
    Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.
    Type: Application
    Filed: June 20, 2017
    Publication date: August 22, 2019
    Applicant: F-STAR DELTA LIMITED
    Inventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis